Valiant Laboratories Ltd

Valiant Laboratories Ltd announced its Board of Directors has approved the acquisition of shares in AMPYR Renewable Energy Resources Twelve A Private Limited for up to ₹70,00,000. This investment is to avail renewable energy under a group captive open access arrangement for its Tarapur plant. AMPYR Renewable Energy Resources Twelve A Private Limited is involved in solar power project development. The acquisition does not involve related parties and is expected to be completed within 12 months.

Valiant Laboratories Ltd announced that its Board of Directors has approved the acquisition of shares in AMPYR Renewable Energy Resources Twelve A Private Limited for an aggregate consideration not exceeding ₹70,00,000. This investment is aimed at availing renewable energy under a group captive open access arrangement for its Tarapur plant. AMPYR Renewable Energy Resources Twelve A Private Limited is involved in solar power generation, with a net worth of ₹9.99 Crore and a turnover of ₹23.26 Crore as of March 31, 2026. The acquisition, which does not involve related parties, is expected to be completed within 12 months and will not alter the control or management of the target entity.

Valiant Laboratories Ltd. has dispatched letters to shareholders who have not registered their email addresses, providing access to the Annual Report for FY 2025-26 and the Notice for the 5th Annual General Meeting (AGM). The AGM is scheduled for September 28, 2026, via Video Conferencing. Shareholders can access these documents online through a provided web-link and on the company's and stock exchanges' websites. Instructions are also given for shareholders to update their email addresses for future communications.

Valiant Laboratories Ltd has announced its 5th Annual General Meeting (AGM) scheduled for September 28, 2026, at 11:30 a.m. IST, to be conducted via Video Conferencing/Other Audio Visual Means. The company has also released its Annual Report for the Financial Year 2025-26. In compliance with SEBI and MCA circulars, the notice and report are being sent electronically to members registered as of August 28, 2026. The Annual Report details the company's performance, including financial highlights, manufacturing, supply chain, ESG initiatives, leadership, and statutory reports. It also contains forward-looking statements regarding future plans and market conditions. The report is available on the company's website.

Valiant Laboratories Ltd has released its Annual Report for the Financial Year 2025-26, along with the Notice for its 5th Annual General Meeting (AGM). The AGM is scheduled for Monday, September 28, 2026, at 11:30 a.m. IST, to be conducted via Video Conferencing/Other Audio Visual Means. The report, detailing the company's performance, financial highlights, manufacturing, supply chain, ESG initiatives, and corporate governance, is available on the company's website. The company highlights its journey of transforming potential into progress over 45 years, emphasizing its role as a leading API manufacturer within the Aarti Group.

Valiant Laboratories Ltd has submitted its Monitoring Agency Report for the quarter ended June 30, 2026. The report, issued by India Ratings and Research Private Limited, confirms that funds raised through the company's Rights Issue, as detailed in the Letter of Offer dated July 15, 2025, have been utilized appropriately for the stated objects. No deviation from the objects of the issue was observed, as verified by a Statutory Auditor Certificate. The report has been reviewed by the Audit Committee and the Board of Directors.

Valiant Laboratories Limited's Board of Directors convened on August 10, 2026, approving several key decisions. The company will invest up to ₹60 Crore in its wholly-owned subsidiary, Valiant Advanced Sciences Private Limited (VASPL), through Optionally Convertible Redeemable Preference Shares. The board also approved the re-appointment of Mr. Santosh Vora as Managing Director for five years and Mrs. Sonal Vira as Independent Director for a second five-year term, both subject to member approval. Additionally, the continuation of Mr. Shantilal Vora's directorship as Non-Executive Non-Independent Director was recommended. The company also plans to shift its registered office and open a new corporate office.

Valiant Laboratories Ltd announced key board decisions including the re-appointment of Mr. Santosh Vora as Managing Director for five years from February 06, 2027, and Mrs. Sonal Vira as Independent Director for a second five-year term from February 16, 2027. The board also approved the continuation of Mr. Shantilal Vora as Non-Executive Non-Independent Director from November 05, 2027. Additionally, the company plans to shift its registered office and open a new corporate office. An investment of up to ₹60 Crore in its wholly-owned subsidiary, Valiant Advanced Sciences Private Limited, was also approved.

Valiant Laboratories Ltd announced a significant shift in its registered office from Mumbai to Palghar, Maharashtra, subject to shareholder and regulatory approvals. The company's Board of Directors also approved the re-appointment of Mr. Santosh Vora as Managing Director for five years and Mrs. Sonal Vira as Independent Director for a second five-year term. Additionally, the continuation of Mr. Shantilal Vora's directorship was approved. The company also plans to open a new corporate office in Vikhroli, Mumbai, and invest up to ₹60 Crore in its subsidiary, Valiant Advanced Sciences Private Limited.

Valiant Laboratories Limited announced key decisions from its Board of Directors meeting held on August 10, 2026. The board approved the re-appointment of Mr. Santosh Vora as Managing Director for five years and Mrs. Sonal Vira as Independent Director for a second five-year term. Continuation of Mr. Shantilal Vora's directorship was also recommended. The company will shift its registered office and open a new corporate office in Mumbai. Additionally, an investment of up to ₹60 Crore in its wholly-owned subsidiary, Valiant Advanced Sciences Private Limited (VASPL), through Optionally Convertible Redeemable Preference Shares was approved. All re-appointments and the continuation of directorship are subject to member approval via Special Resolution at the upcoming AGM.